On September 3, 2025, the US Food and Drug Administration (FDA) introduced the Rare Disease Evidence Principles (RDEP) process, a groundbreaking step for drug development targeting ultra-rare genetic diseases. According to Cooley.com, the RDEP framework provides much-needed clarity for sponsors developing therapies for conditions affecting very small patient populations (typically fewer than 1,000 individuals in the US) where traditional large, randomized trials are often impossible.
A Tailored Approach to Evidence
Previously, the FDA could approve drugs for rare diseases based on a single pivotal clinical trial backed by additional confirmatory evidence. The RDEP process formalizes and expands upon this flexibility, outlining clear guidelines for what constitutes “substantial evidence” of effectiveness in these challenging scenarios. Under RDEP, a single, well-controlled trial—often a single-arm study—may suffice if robust confirmatory data supports the findings. Acceptable confirmatory evidence includes:
- Data showing the drug’s effect on disease mechanisms,
- Results from relevant nonclinical (lab or animal) models,
- Clinical pharmacodynamic data,
- Case reports and expanded access data.
This approach acknowledges the practical limitations in rare disease research, where recruiting large cohorts is unfeasible and disease progression is rapid and severe.
Eligibility and Process
To qualify for RDEP, therapies must address diseases caused by known genetic defects with no existing effective treatments and lead to significant disability or death within a short period. The disease population must be tiny, meaning less than 1,000 people, which is much stricter than the 200,000-person threshold for orphan drugs. RDEP is limited to genetically defined diseases, meaning some rare conditions, such as those without clear genetic origins, may not be eligible.
Sponsors can apply for RDEP consideration before launching pivotal trials, allowing for early dialogue with the FDA. This pre-trial engagement gives sponsors upfront assurance about the sufficiency of a single pivotal trial and associated data, potentially saving significant time and resources.
Implications for Innovation and Investment
The RDEP process is not a radical departure from previous FDA practice but codifies existing flexibilities and provides a more predictable regulatory pathway. This certainty is expected to boost investor confidence, as it reduces uncertainty around trial requirements and accelerates the development timeline for promising therapies. Investors may see this as a signal of the FDA’s strong commitment to supporting rare disease innovation, potentially attracting more capital, partnerships, and strategic interest in the field.
Strengthening the Rare Disease Ecosystem
By clarifying requirements and streamlining communication between sponsors and regulators, RDEP aims to accelerate life-changing therapies for patients with ultra-rare genetic diseases. The framework also encourages collaboration between regulatory divisions through the Rare Disease Policy and Portfolio Council, facilitating a unified approach to complex rare disease challenges.
